Developer docs
API playgroundTry for free, no card

Search company profiles

EyePoint Pharmaceuticals

Full company profile

uuid000458m

Namestring
EyePoint Pharmaceuticals
Legal namestring
EyePoint, Inc.
Company typeenum
Public
Founded yearint
2008
Descriptiontext

EyePoint Pharmaceuticals (now operating as EyePoint, Inc.) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts that develops sustained-release therapeutics for serious retinal diseases. The company's core technology is the proprietary Durasert E™ bio-erodible delivery platform, which enables sustained intraocular drug release over approximately six months per dose; this platform has been validated through four FDA-approved products, and EyePoint currently markets two of them commercially: YUTIQ, a three-year intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a single-dose steroid for post-cataract inflammation. Lead pipeline asset DURAVYU (vorolanib intravitreal insert) combines a multi-mechanism tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 with the Durasert E platform, and is currently in Phase 3 trials for wet age-related macular degeneration (LUGANO) and diabetic macular edema (COMO and CAPRI).

The company's commercial business model today is small and declining, with FY2025 revenue of $31.4 million driven largely by deferred revenue recognition from a 2023 YUTIQ licensing agreement, and an annualized run rate that has dropped below $5 million as that deferred revenue winds down. Pricing for the investigational DURAVYU has not been publicly disclosed, and the company has historically supplemented product sales with royalty arrangements, including a March 2025 transaction that sold a 3.125% perpetual royalty on YUTIQ and ILUVIEN net revenues to SWK Funding for $17.25 million. EyePoint has raised approximately $172.5 million in oversubscribed public equity financing in October 2025, holds roughly $300-306 million in cash extending runway into Q4 2027, and is investing in commercial readiness through executive hires (including a Chief Commercial Officer recruited from the Genentech Lucentis launch team) and manufacturing scale-up at its Northbridge, MA facility.

Short descriptiontext

EyePoint is a clinical-stage biopharmaceutical company developing sustained-release ophthalmic therapeutics using its proprietary Durasert E™ platform, with lead asset DURAVYU in Phase 3 trials for wet AMD and diabetic macular edema, plus two FDA-approved commercial products, YUTIQ and DEXYCU.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sustained-release ophthalmics, retinal disease therapeutics, intravitreal drug delivery, ophthalmic pharmaceuticals, tyrosine kinase inhibitors
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals (Retinal Disease Therapeutics)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Commercialized Drugs)
TypeOne Time License
Description

Revenue generated from FDA-approved products YUTIQ and DEXYCU. YUTIQ is an intravitreal implant for chronic non-infectious uveitis, and DEXYCU is for postoperative inflammation following cataract surgery. Revenue has been declining, with Q3 2025 revenue of $1.0 million down from $10.5 million in Q3 2024 primarily due to recognition of remaining deferred revenue from 2023 YUTIQ licensing agreement.

globenewswire.com
2Licensing Royalties
TypeLicensing Royalties
Description

EyePoint has historically received royalty payments from licensing agreements, including the 2023 YUTIQ licensing agreement that contributed to prior year revenue recognition. The company sold a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues to SWK Funding LLC for USD 17.25 million in March 2025.

globenewswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1DURAVYU
Description

Lead investigational product candidate - sustained-release tyrosine kinase inhibitor (TKI) for serious retinal diseases, combining vorolanib with Durasert E technology

eyepoint.bio
+2 more records
Core offering1 text field

EyePoint Pharmaceuticals is a clinical-stage and commercial biopharmaceutical company developing and selling sustained-release ophthalmic therapeutics for serious retinal and ocular diseases. Its lead investigational product, DURAVYU, combines the tyrosine kinase inhibitor vorolanib with the proprietary Durasert E bioerodible delivery technology for intravitreal treatment of diabetic macular edema, wet AMD, and retinal vein occlusion. Commercial offerings include YUTIQ, a 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a 9% dexamethasone suspension for postoperative inflammation following cataract surgery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 80% reduction in treatment burden compared to standard aflibercept injections in Phase 2 trials
+2 more records
Product overview1 text field

EyePoint is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases. The company's portfolio consists of its lead investigational product DURAVYU (vorolanib intravitreal insert) in Phase 3 trials for wet AMD and diabetic macular edema, two FDA-approved commercial products (YUTIQ and DEXYCU), and a proprietary Durasert drug delivery technology platform that has supported four FDA-approved products. The Durasert technology enables sustained intraocular delivery of therapeutic agents, with DURAVYU specifically utilizing the next-generation Durasert E platform to provide approximately six-month dosing compared to standard anti-VEGF injections that require dosing every few weeks.

Product and service1 record
1DURAVYU (vorolanib in Durasert E)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1American College of Eye Technicians (ACET)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

EyePoint is one of several pharmaceutical companies (including Alcon, Bausch + Lomb, Dompe, RxSight, and Topcon Healthcare) subsidizing training costs for ACET's 8-week virtual ophthalmic technician training program to address workforce shortages in the ophthalmology field.

glance.eyesoneyecare.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Acquired IVERIC bio for Izervay (avacincaptad pegol), a complement inhibitor for geographic atrophy. Comparable as a recently launched ophthalmology biopharma targeting retinal disease.

TypeDirect peer
Description

Markets Beovu (brolucizumab) for wet AMD, a competing anti-VEGF therapy in the same retinal disease space where DURAVYU is being developed.

TypeEmerging player
Description

Developing ONS-5010 / Lytenava, an ophthalmic formulation of bevacizumab for wet AMD. Comparable as a late-stage ophthalmology biopharma pursuing wet AMD market entry.

TypeEmerging player
Description

Develops suprachoroidal delivery-based therapies for retinal diseases including XIPERE for macular edema. Comparable on novel intraocular drug delivery and ophthalmology specialty focus.

TypeEmerging player
Description

Developing gene therapies (ADVM-022 / ixoberogene soroparvovec) for wet AMD with the goal of reducing injection frequency. Closely comparable on the sustained-release / reduced-burden value proposition.

TypeEmerging player
Description

Clinical-stage biotech developing OPT-302 for wet AMD. Highly comparable as a small-cap ophthalmology biotech with Michael Campbell previously serving as COO.

TypeDirect peer
Description

Markets Lucentis and Vabysmo for wet AMD and DME. Vabysmo's extended dosing interval is the closest direct competitor to DURAVYU's 6-month sustained-release proposition.

TypeDirect peer
Description

Develops and markets Eylea and Eylea HD, the leading anti-VEGF therapies for wet AMD and DME. Most directly comparable as the dominant incumbent in the same indications DURAVYU targets.

TypeEmerging player
Description

Clinical-stage biotech developing antibody biopolymer conjugates for retinal vascular diseases including wet AMD. Comparable as a retinal-focused biotech with similar development-stage risk profile.

TypeDirect peer
Description

Develops Syfovre for geographic atrophy and is a clinical-stage ophthalmology peer with similar development-stage dynamics and focus on retinal disease therapeutics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EyePoint Pharmaceuticals

Ophthalmic Pharmaceuticals (Retinal Disease Therapeutics)eyepointpharma.com

EyePoint is a clinical-stage biopharmaceutical company developing sustained-release ophthalmic therapeutics using its proprietary Durasert E™ platform, with lead asset DURAVYU in Phase 3 trials for wet AMD and diabetic macular edema, plus two FDA-approved commercial products, YUTIQ and DEXYCU.

What EyePoint Pharmaceuticals does

EyePoint Pharmaceuticals (now operating as EyePoint, Inc.) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts that develops sustained-release therapeutics for serious retinal diseases. The company's core technology is the proprietary Durasert E™ bio-erodible delivery platform, which enables sustained intraocular drug release over approximately six months per dose; this platform has been validated through four FDA-approved products, and EyePoint currently markets two of them commercially: YUTIQ, a three-year intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a single-dose steroid for post-cataract inflammation. Lead pipeline asset DURAVYU (vorolanib intravitreal insert) combines a multi-mechanism tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 with the Durasert E platform, and is currently in Phase 3 trials for wet age-related macular degeneration (LUGANO) and diabetic macular edema (COMO and CAPRI).

The company's commercial business model today is small and declining, with FY2025 revenue of $31.4 million driven largely by deferred revenue recognition from a 2023 YUTIQ licensing agreement, and an annualized run rate that has dropped below $5 million as that deferred revenue winds down. Pricing for the investigational DURAVYU has not been publicly disclosed, and the company has historically supplemented product sales with royalty arrangements, including a March 2025 transaction that sold a 3.125% perpetual royalty on YUTIQ and ILUVIEN net revenues to SWK Funding for $17.25 million. EyePoint has raised approximately $172.5 million in oversubscribed public equity financing in October 2025, holds roughly $300-306 million in cash extending runway into Q4 2027, and is investing in commercial readiness through executive hires (including a Chief Commercial Officer recruited from the Genentech Lucentis launch team) and manufacturing scale-up at its Northbridge, MA facility.

EyePoint Pharmaceuticals firmographics

Firmographics
Name
EyePoint Pharmaceuticals
Legal name
EyePoint, Inc.
Website
https://eyepointpharma.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
251–500 employees
Short description
EyePoint is a clinical-stage biopharmaceutical company developing sustained-release ophthalmic therapeutics using its proprietary Durasert E™ platform, with lead asset DURAVYU in Phase 3 trials for wet AMD and diabetic macular edema, plus two FDA-approved commercial products, YUTIQ and DEXYCU.
Ownership category
akta.pro rank

EyePoint Pharmaceuticals industry classification

Industry
Product category
Ophthalmic Pharmaceuticals (Retinal Disease Therapeutics)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Sustained-release ophthalmics
  • Retinal disease therapeutics
  • Intravitreal drug delivery
  • Ophthalmic pharmaceuticals
  • Tyrosine kinase inhibitors

Where EyePoint Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EyePoint Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Sales (Commercialized Drugs): Revenue generated from FDA-approved products YUTIQ and DEXYCU. YUTIQ is an intravitreal implant for chronic non-infectious uveitis, and DEXYCU is for postoperative inflammation following cataract surgery. Revenue has been declining, with Q3 2025 revenue of $1.0 million down from $10.5 million in Q3 2024 primarily due to recognition of remaining deferred revenue from 2023 YUTIQ licensing agreement.
  2. Licensing Royalties: EyePoint has historically received royalty payments from licensing agreements, including the 2023 YUTIQ licensing agreement that contributed to prior year revenue recognition. The company sold a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues to SWK Funding LLC for USD 17.25 million in March 2025.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

EyePoint Pharmaceuticals product offering

Product offering

Core offering

EyePoint Pharmaceuticals is a clinical-stage and commercial biopharmaceutical company developing and selling sustained-release ophthalmic therapeutics for serious retinal and ocular diseases. Its lead investigational product, DURAVYU, combines the tyrosine kinase inhibitor vorolanib with the proprietary Durasert E bioerodible delivery technology for intravitreal treatment of diabetic macular edema, wet AMD, and retinal vein occlusion. Commercial offerings include YUTIQ, a 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a 9% dexamethasone suspension for postoperative inflammation following cataract surgery.

Product overview

EyePoint is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases. The company's portfolio consists of its lead investigational product DURAVYU (vorolanib intravitreal insert) in Phase 3 trials for wet AMD and diabetic macular edema, two FDA-approved commercial products (YUTIQ and DEXYCU), and a proprietary Durasert drug delivery technology platform that has supported four FDA-approved products. The Durasert technology enables sustained intraocular delivery of therapeutic agents, with DURAVYU specifically utilizing the next-generation Durasert E platform to provide approximately six-month dosing compared to standard anti-VEGF injections that require dosing every few weeks.

Differentiator

Problem solved

Functional benefit

Brands

  • DURAVYU: Lead investigational product candidate - sustained-release tyrosine kinase inhibitor (TKI) for serious retinal diseases, combining vorolanib with Durasert E technology
  • Durasert E
  • Durasert

Products and services

  • DURAVYU (vorolanib in Durasert E)

Quantifiable outcome

  • Over 80% reduction in treatment burden compared to standard aflibercept injections in Phase 2 trials
  • +2 more outcomes

Companies that use EyePoint Pharmaceuticals

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

EyePoint Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

EyePoint Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • American College of Eye Technicians (ACET)minorStrategic or Co-development Partner · 1 January 2026EyePoint is one of several pharmaceutical companies (including Alcon, Bausch + Lomb, Dompe, RxSight, and Topcon Healthcare) subsidizing training costs for ACET's 8-week virtual ophthalmic technician training program to address workforce shortages in the ophthalmology field.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

EyePoint Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Astellas Pharma (IVERIC bio): Acquired IVERIC bio for Izervay (avacincaptad pegol), a complement inhibitor for geographic atrophy. Comparable as a recently launched ophthalmology biopharma targeting retinal disease.
  • Novartis: Markets Beovu (brolucizumab) for wet AMD, a competing anti-VEGF therapy in the same retinal disease space where DURAVYU is being developed.
  • Roche / Genentech: Markets Lucentis and Vabysmo for wet AMD and DME. Vabysmo's extended dosing interval is the closest direct competitor to DURAVYU's 6-month sustained-release proposition.
  • Regeneron Pharmaceuticals: Develops and markets Eylea and Eylea HD, the leading anti-VEGF therapies for wet AMD and DME. Most directly comparable as the dominant incumbent in the same indications DURAVYU targets.
  • Apellis Pharmaceuticals: Develops Syfovre for geographic atrophy and is a clinical-stage ophthalmology peer with similar development-stage dynamics and focus on retinal disease therapeutics.

Emerging players

  • Outlook Therapeutics: Developing ONS-5010 / Lytenava, an ophthalmic formulation of bevacizumab for wet AMD. Comparable as a late-stage ophthalmology biopharma pursuing wet AMD market entry.
  • Clearside Biomedical: Develops suprachoroidal delivery-based therapies for retinal diseases including XIPERE for macular edema. Comparable on novel intraocular drug delivery and ophthalmology specialty focus.
  • Adverum Biotechnologies: Developing gene therapies (ADVM-022 / ixoberogene soroparvovec) for wet AMD with the goal of reducing injection frequency. Closely comparable on the sustained-release / reduced-burden value proposition.
  • Opthea: Clinical-stage biotech developing OPT-302 for wet AMD. Highly comparable as a small-cap ophthalmology biotech with Michael Campbell previously serving as COO.
  • Kodiak Sciences: Clinical-stage biotech developing antibody biopolymer conjugates for retinal vascular diseases including wet AMD. Comparable as a retinal-focused biotech with similar development-stage risk profile.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

EyePoint Pharmaceuticals social profiles

Digital presence

EyePoint Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EyePoint Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles14 records

EyePoint Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EyePoint Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EyePoint Pharmaceuticals

What does EyePoint Pharmaceuticals do?

EyePoint Pharmaceuticals is a clinical-stage and commercial biopharmaceutical company developing and selling sustained-release ophthalmic therapeutics for serious retinal and ocular diseases. Its lead investigational product, DURAVYU, combines the tyrosine kinase inhibitor vorolanib with the proprietary Durasert E bioerodible delivery technology for intravitreal treatment of diabetic macular edema, wet AMD, and retinal vein occlusion. Commercial offerings include YUTIQ, a 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a 9% dexamethasone suspension for postoperative inflammation following cataract surgery.

Is EyePoint Pharmaceuticals a public or private company?

EyePoint Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was EyePoint Pharmaceuticals founded?

EyePoint Pharmaceuticals was founded in 2008. It employs 251 to 500 people.

Where is EyePoint Pharmaceuticals based?

EyePoint Pharmaceuticals is headquartered in Watertown, United States, in the North America region.

How does EyePoint Pharmaceuticals make money?

Two revenue lines are on record. Product Sales (Commercialized Drugs) is the primary driver. The others are licensing Royalties.

Who are EyePoint Pharmaceuticals's main competitors?

Direct peers on record are Astellas Pharma (IVERIC bio), Novartis, Roche / Genentech, Regeneron Pharmaceuticals and Apellis Pharmaceuticals. Emerging players are Outlook Therapeutics, Clearside Biomedical, Adverum Biotechnologies, Opthea and Kodiak Sciences.

Does EyePoint Pharmaceuticals have an API?

No public API is recorded for EyePoint Pharmaceuticals.

What industry is EyePoint Pharmaceuticals in?

EyePoint Pharmaceuticals's product category is Ophthalmic Pharmaceuticals (Retinal Disease Therapeutics). Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEYPT Investors Have Opportunity to Lead EyePoint, Inc. Securities Fraud LawsuitRosen Law Firm announced a securities class action against EyePoint, Inc. for alleged false statements about its lead product DURAVYU, covering purchases from May 27, 2025 to August 14, 2026. The lawsuit claims the product was less effective than represented, overstating its prospects. Lead plaintiff must move by January 19, 2027.FinancialContent Business PageRosen Law Firm Urges EyePoint, Inc. (NASDAQ: EYPT) Stockholders to Contact the Firm for Information About Their RightsRosen Law Firm announced a securities class action against EyePoint, Inc. over alleged misleading statements about DURAVYU's effectiveness. The lawsuit claims the product was less effective than represented, overstating its clinical and commercial prospects. Shareholders may serve as lead plaintiff by January 19, 2027.GlobeNewswireEYPT INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of EyePoint, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmA shareholder class action lawsuit was filed against EyePoint, alleging false statements about DURAVYU's effectiveness. The lawsuit claims DURAVYU's prospects were overstated, and investors who lost money between May 27, 2025 and August 14, 2026 are encouraged to contact the firm. The deadline to seek lead plaintiff appointment is January 19, 2027.FinancialContent Business PageInvestor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action LawsuitRobbins LLP informed investors of a class action against EyePoint, Inc. over alleged misrepresentation of DURAVYU's efficacy in wet AMD trials. The lawsuit cites a stock drop of 66.98% after LUGANO trial results and an 85.28% drop after LUCIA trial results and program termination. Investors may seek lead plaintiff appointment.Seeking AlphaEyePoint, Inc. (EYPT) Presents at UBS Global Biopharma Conference 2026 TranscriptEyePoint's CEO Jay Duker presented at the UBS Global Biopharma Conference, stating that its Phase III wet AMD trials (LUGANO and LUCIA) did not meet the primary non-inferiority endpoint against Eylea. The company has two fully enrolled diabetic macular edema trials.Investing.comEyePoint at UBS biopharma conference: DME hopes offset wet AMD setbackEyePoint Pharmaceuticals reported that its DURAVYU drug failed the primary non-inferiority endpoint in two wet AMD Phase III trials, but showed strong secondary data on fluid control and safety. The company now focuses on its Phase III DME program, with top-line results expected in early Q4 2025. Management said a DME-only label could be commercially meaningful.TradingViewEyePoint, Inc. Stock 12‑Month Price Target Cut to $10.44, Implies 3311% UpsideAnalysts' average price target for EyePoint, Inc. fell from $12.28 to $10.44, implying about 3311% upside from the Nov. 13 closing price. The consensus rating remains Hold across 13 analysts, with 3 Buys, 9 Holds, and 1 Sell.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPomerantz LLP is investigating securities fraud claims against EyePoint, Inc. after two failed Phase 3 trials for its wet AMD drug Duravyu. The company's stock fell 66.98% after the first trial and 85.28% after the second, prompting a 53% workforce cut.PRESSBEEINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ...Middle EastPomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (NASDAQ: EYPT). The law firm advises investors to contact Danielle Peyton at the provided email or phone number.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPomerantz LLP is investigating securities fraud claims on behalf of EyePoint investors after two failed Phase 3 trials for its wet AMD drug Duravyu. The company's stock fell 66.98% and 85.28% following the results, and it cut its workforce by 53%.